Critical Reagent Screening and Characterization: Benefits and Approaches for Protein Biomarker Assays by Hybrid LC–MS

References

• Van Den Broek I , NoutaJ, RazaviMet al. Quantification of serum apolipoproteins A-I and B-100 in clinical samples using an automated SISCAPA–MALDI-TOF-MS workflow. Methods81, 74–85 (2015).
   PubMed Web of Science ®Google Scholar
• Halfinger B , Hammerer-LercherA, AmplatzB, SargB, KremserL, LindnerHH. Unraveling the molecular complexity of O-glycosylated endogenous (N-terminal) pro–B-type natriuretic peptide forms in blood plasma of patients with severe heart failure. Clin. Chem.63(1), 359–368 (2017).
   PubMed Web of Science ®Google Scholar
• Torma Attila F , GrovesK, BiesenbruchSet al. A candidate liquid chromatography mass spectrometry reference method for the quantification of the cardiac marker 1-32 B-type natriuretic peptide. Clin. Chem. Lab. Med.55(9), 1397 (2017).
   PubMed Web of Science ®Google Scholar
• Burns EC , DhoddaR, Pasas-FarmerSet al. Report on the 18th Annual Land O’Lakes Bioanalytical Conference. Bioanalysis10(7), 445–449 (2018).
   PubMed Web of Science ®Google Scholar
• Schneck NA , PhinneyKW, LeeSB, LowenthalMS. Quantification of cardiac troponin I in human plasma by immunoaffinity enrichment and targeted mass spectrometry. Anal. Bioanal. Chem.410(11), 2805–2813 (2018).
   PubMed Web of Science ®Google Scholar
• Topbas C , SwickA, RazaviM, AndersonNL, PearsonTW, BystromC. Measurement of lipoprotein-associated phospholipase A2 by use of 3 different methods: exploration of discordance between ELISA and activity assays. Clin. Chem.64(4), 697–704 (2018).
   PubMed Web of Science ®Google Scholar
• Becker JO , HoofnagleAN. Replacing immunoassays with tryptic digestion-peptide immunoaffinity enrichment and LC–MS/MS. Bioanalysis4(3), 281–290 (2012).
   PubMed Web of Science ®Google Scholar
• Wheeler SE , LiuL, BlairHCet al. Clinical laboratory verification of thyroglobulin concentrations in the presence of autoantibodies to thyroglobulin: comparison of EIA, radioimmunoassay and LC MS/MS measurements in an urban hospital. BMC Res. Notes10, 725 (2017).
   PubMedGoogle Scholar
• Morgan BR , TarterTH. Serum heterophile antibodies interfere with prostate specific antigen test and result in over treatment in a patient with prostate cancer. J. Urol.166(6), 2311–2312 (2001).
   PubMed Web of Science ®Google Scholar
• Rifai N , GilletteMA, CarrSA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol.24, 971 (2006).
   PubMed Web of Science ®Google Scholar
• Ramagiri S , MooreI. Hybridizing LBA with LC–MS/MS: the new norm for biologics quantification. Bioanalysis8(6), 483–486 (2016).
   PubMed Web of Science ®Google Scholar
• Neubert H , SongA, LeeAet al. 2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays (Part 2: hybrid LBA/LCMS biotherapeutics, biomarkers & immunogenicity assays and regulatory agencies’ inputs). Bioanalysis9(23), 1895–1912 (2017).
   PubMed Web of Science ®Google Scholar
• Cowan KJ , AmaravadiL, CameronMJet al. Recommendations for selection and characterization of protein biomarker assay calibrator material. AAPS J.19(6), 1550–1563 (2017).
   PubMed Web of Science ®Google Scholar
• Nowatzke W , WoolfE. Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples. AAPS J.9(2), E117–E122 (2007).
   PubMed Web of Science ®Google Scholar
• Rup B , O’HaraD. Critical ligand binding reagent preparation/selection: when specificity depends on reagents. AAPS J.9(2), E148–155 (2007).
   PubMed Web of Science ®Google Scholar
• Staack RF , StrackeJO, StubenrauchK, VogelR, SchleypenJ, PapadimitriouA. Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents. Bioanalysis3(5), 523–534 (2011).
   PubMed Web of Science ®Google Scholar
• Nicholson R , LowesS, CaturlaMCet al. Conference report: 6th GCC focus on LBA: critical reagents, positive controls and reference standards; specificity for endogenous compounds; biomarkers; biosimilars. Bioanalysis4(19), 2335–2342 (2012).
   PubMed Web of Science ®Google Scholar
• O’Hara DM , TheobaldV, EganACet al. Ligand binding assays in the 21st Century Laboratory: recommendations for characterization and supply of critical reagents. AAPS J.14(2), 316–328 (2012).
   PubMed Web of Science ®Google Scholar
• Geist BJ , EganAC, YangT-Y, DongY, ShankarG. Characterization of critical reagents in ligand-binding assays: enabling robust bioanalytical methods and lifecycle management. Bioanalysis5(2), 227–244 (2013).
   PubMed Web of Science ®Google Scholar
• King LE , FarleyE, ImazatoMet al. Ligand binding assay critical reagents and their stability: recommendations and best practices from the Global Bioanalysis Consortium Harmonization Team. AAPS J.16(3), 504–515 (2014).
   PubMed Web of Science ®Google Scholar
• Burkitt WI , PritchardC, ArseneC, HenrionA, BunkD, O’ConnorG. Toward Système International d’Unité – traceable protein quantification: from amino acids to proteins. Anal. Biochem.376(2), 242–251 (2008).
   PubMed Web of Science ®Google Scholar
• Kaiser P , AkerboomT, OhlendorfR, ReinauerH. Liquid chromatography–isotope dilution–mass spectrometry as a new basis for the reference measurement procedure for hemoglobin A1c determination. Clin. Chem.56(5), 750–754 (2010).
   PubMed Web of Science ®Google Scholar
• Hirtz C , BrosP, BredeCet al. Regulatory context and validation of assays for clinical mass spectrometry proteomics (cMSP) methods. Crit. Rev. Clin. Lab. Sci.55(5), 346–358 (2018).
   PubMed Web of Science ®Google Scholar
• Miao Q , BoA, ShichenSet al. Qualitative and quantitative characterization of protein biotherapeutics with liquid chromatography mass spectrometry. Mass Spectrom. Rev.36(6), 734–754 (2017).
   PubMed Web of Science ®Google Scholar
• Stevenson L , AmaravadiL, MylerHet al. 2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 – LBA and immunogenicity). Bioanalysis6(24), 3355–3368 (2014).
   PubMed Web of Science ®Google Scholar
• Amaravadi L , SongA, MylerHet al. 2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3 – LBA, biomarkers and immunogenicity). Bioanalysis7(24), 3107–3124 (2015).
   PubMed Web of Science ®Google Scholar
• Kubiak RJ , LeeN, ZhuYet al. Storage conditions of conjugated reagents can impact results of immunogenicity assays. J. Immunol. Res.2016, 1485615 (2016).
   PubMed Web of Science ®Google Scholar
• Richards S , AmaravadiL, PillutlaRet al. 2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 3 – LBA, biomarkers and immunogenicity). Bioanalysis8(23), 2475–2496 (2016).
   PubMed Web of Science ®Google Scholar
• Gupta S , RichardsS, AmaravadiLet al. 2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 – LBA: immunogenicity, biomarkers and PK assays). Bioanalysis9(24), 1967–1996 (2017).
   PubMed Web of Science ®Google Scholar
• Weiß F , VanDen Berg BHJ, PlanatscherH, PynnCJ, JoosTO, PoetzO. Catch and measure – mass spectrometry‐based immunoassays in biomarker research. Biochimic. Biophys. Acta1844(5), 927–932 (2014).
   PubMed Web of Science ®Google Scholar
• Boterman M , DoigM, BredaMet al. Recommendations on the interpretation of the new European Medicines Agency Guideline on Bioanalytical Method Validation by Global CRO Council for Bioanalysis (GCC). Bioanalysis4(6), 651–660 (2012).
   PubMed Web of Science ®Google Scholar
• Lee J , MaH. Specificity and selectivity evaluations of ligand binding assay of protein therapeutics against concomitant drugs and related endogenous proteins. AAPS J.9(2), E164–E170 (2007).
   PubMed Web of Science ®Google Scholar
• Duggan JX , VazvaeiF, JenkinsR. Bioanalytical method validation considerations for LC–MS/MS assays of therapeutic proteins. Bioanalysis7(11), 1389–1395 (2015).
   PubMed Web of Science ®Google Scholar
• Ahn YH , KimKH, ShinPM, JiES, KimH, YooJS. Identification of low-abundance cancer biomarker candidate TIMP1 from serum with lectin fractionation and peptide affinity enrichment by ultrahigh-resolution mass spectrometry. Anal. Chem.84(3), 1425–1431 (2012).
   PubMed Web of Science ®Google Scholar
• Anderson L , HunterCL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics5(4), 573–588 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson NL , AndersonNG, HainesLR, HardieDB, OlafsonRW, PearsonTW. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J. Proteome Res.3(2), 235–244 (2004).
   PubMed Web of Science ®Google Scholar
• Anderson NL , JacksonA, SmithD, HardieD, BorchersC, PearsonTW. SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device. Mol. Cell. Proteomics8(5), 995–1005 (2009).
   PubMed Web of Science ®Google Scholar
• Kuhn E , AddonaT, KeshishianHet al. Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin. Chem.55(6), 1108–1117 (2009).
   PubMed Web of Science ®Google Scholar
• Kuhn E , WhiteakerJR, ManiDRet al. Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. Mol. Cell. Proteomics11(6), M111.013854 (2012).
   Google Scholar
• Schoenherr RM , ZhaoL, WhiteakerJRet al. Automated screening of monoclonal antibodies for SISCAPA assays using a magnetic bead processor and liquid chromatography-selected reaction monitoring-mass spectrometry. J. Immunol. Methods353(1-2), 49–61 (2010).
   PubMed Web of Science ®Google Scholar
• Whiteaker JR , ZhaoL, AbbatielloSEet al. Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol. Cell. Proteomics10(4), M110.005645 (2011).
   Google Scholar
• Whiteaker JR , ZhaoL, AndersonL, PaulovichAG. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol. Cell. Proteomics9(1), 184–196 (2010).
   PubMed Web of Science ®Google Scholar
• Zhao L , WhiteakerJR, PopeMEet al. Quantification of proteins using peptide immunoaffinity enrichment coupled with mass spectrometry. J. Vis. Exp.2011(53), 2812 (2011).
   Google Scholar
• Baker M . Antibody anarchy: a call to order. Nature527, 545 (2015).
   PubMed Web of Science ®Google Scholar
• Prassas I , BrincD, FarkonaSet al. False biomarker discovery due to reactivity of a commercial eLISA for CUZD1 with cancer antigen CA125. Clin. Chem.60(2), 381–388 (2014).
   PubMed Web of Science ®Google Scholar
• Füzéry AK , LevinJ, ChanMM, ChanDW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin. Proteomics10(1), 13–13 (2013).
   PubMed Web of Science ®Google Scholar
• Ni YG , YuanX, NewittJAet al. Development and fit-for-purpose validation of a soluble human programmed death-1 protein assay. AAPS J.17(4), 976–987 (2015).
   PubMed Web of Science ®Google Scholar
• Bradbury ARM , TrinkleinND, ThieHet al. When monoclonal antibodies are not monospecific: hybridomas frequently express additional functional variable regions. mAbs10(4), 539–546 (2018).
   PubMed Web of Science ®Google Scholar
• Abdiche Y , MalashockD, PinkertonA, PonsJ. Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet. Anal. Biochem.377(2), 209–217 (2008).
   PubMed Web of Science ®Google Scholar
• Duo J , BrunoJ, PiccoliS, DesilvaB, ZhangYJ. Characterization of labeled reagents in ligand-binding assays by a surface plasmon resonance biosensor. Bioanalysis9(2), 193–207 (2017).
   PubMed Web of Science ®Google Scholar
• Fraser S , ShihJY, WareMet al. Current trends in ligand binding real-time measurement technologies. AAPS J.19(3), 682–691 (2017).
   PubMed Web of Science ®Google Scholar
• Genick CC , WrightSK. Biophysics: for HTS hit validation, chemical lead optimization, and beyond. Expert Opin. Drug Dis.12(9), 897–907 (2017).
   PubMed Web of Science ®Google Scholar
• Martinez-Perdiguero J , RetolazaA, BujandaL, MerinoS. Surface plasmon resonance immunoassay for the detection of the TNFα biomarker in human serum. Talanta119, 492–497 (2014).
   PubMed Web of Science ®Google Scholar
• Riedel T , MajekP, Rodriguez-EmmeneggerC, BryndaE. Surface plasmon resonance: advances of label-free approaches in the analysis of biological samples. Bioanalysis6(24), 3325–3336 (2014).
   PubMed Web of Science ®Google Scholar
• Razavi M , PopeME, SosteMVet al. MALDI immunoscreening (MiSCREEN): a method for selection of anti-peptide monoclonal antibodies for use in immunoproteomics. J. Immunol. Methods364(1-2), 50–64 (2011).
   PubMed Web of Science ®Google Scholar
• Otieno BA , KrauseCE, RuslingJF. Chapter seven - bioconjugation of antibodies and enzyme labels onto magnetic beads. In: Methods EnzymologyKumarCV ( Ed.). Academic Press Cambridge, MA, USA, 135–150 (2016).
   Google Scholar
• Nicholas Welch G . Orientation and characterization of immobilized antibodies for improved immunoassays (Review). Biointerphases12(2), 02D301 (2017).
   PubMed Web of Science ®Google Scholar
• Säll A , WalleM, WingrenCet al. Generation and analyses of human synthetic antibody libraries and their application for protein microarrays. Protein Eng., Des. Sel.29(10), 427–437 (2016).
   PubMed Web of Science ®Google Scholar
• Duo J , BrunoJ, KozhichAet al. Surface plasmon resonance as a tool for ligand-binding assay reagent characterization in bioanalysis of biotherapeutics. Bioanalysis10(8), 559–576 (2018).
   PubMed Web of Science ®Google Scholar
• Säll A , CorbeeD, VikströmS, OttossonF, PerssonH, WaldemarsonS. Advancing the immunoaffinity platform AFFIRM to targeted measurements of proteins in serum in the pg/ml range. PLoS ONE13(2), e0189116 (2018).
   PubMed Web of Science ®Google Scholar
• Kaltashov IA , BobstCE, AbzalimovRR, WangG, BaykalB, WangS. Advances and challenges in analytical characterization of biotechnology products: mass spectrometry-based approaches to study properties and behavior of protein therapeutics. Biotechnol. Adv.30(1), 210–222 (2012).
   PubMed Web of Science ®Google Scholar
• Haulenbeek J , PiccoliSP. Conjugated critical reagent characterization for ligand-binding assays: using MALDI-TOF-MS as an orthogonal tool to assess assay performance. Bioanalysis6(7), 983–992 (2014).
   PubMed Web of Science ®Google Scholar